drugset / Trial / NCT04682509
A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation
NaSingle-groupOpen-labelPrevention
Summary
The purpose of this research study is to evaluate the feasibility of a 2 week course of glecaprevir/pibrentasvir (Mavyret) starting immediately prior to transplantation to treat hepatitis C virus (HCV) in kidney transplant recipients who receive a kidney from a donor with HCV.
Timeline
- Start
- 2022-03-20
- Primary completion
- 2023-05-16
- Completion
- 2024-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | glecaprevir | Other / unclassified | 300 mg | Oral |
| Subject | pibrentasvir | Other / unclassified | 120 mg | Oral |